

NextCell to present at the INNODIA Symposium during EASD 2026

NextCell Pharma AB (publ) ("NextCell" or the "Company") has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell's clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

INNODIA is a European network bringing together researchers, clinicians and drug developers in the field of type 1 diabetes. NextCell's CEO, Mathias Svahn, will present during the conference's cell therapy session.

The published conference material states that NextCell will present topline results from the ProTrans-Young study. The study is sponsored by Uppsala University, and NextCell has not yet received access to the study data. Therefore, no results from ProTrans-Young will be presented at the conference. The results will be presented separately once they become available.

"It is valuable for NextCell to present our programme in this setting alongside other leading organisations working in type 1 diabetes. We will focus on the clinical data currently available to us and on the continued development of NXTCL-T1D," says Mathias Svahn, CEO of NextCell Pharma.

For more information, please contact:

Mathias Svahn, CEO

Eric Gustafsson, CFO

Tel: +46 (0)8-735 55 95

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.

RedEye Noridc Growth AB is the company's Certified Adviser.

About NextCell Pharma AB

NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company's lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.